What is Telesair?
Founded in 2020 and headquartered in Irvine, California, Telesair is dedicated to developing innovative, compact, and mobile respiratory care solutions. The company targets hospitals, long-term care facilities, skilled nursing providers, rural health organizations, and the homecare market. Telesair's platform leverages state-of-the-art sensor fusion technologies and advanced pneumatics, aiming to enhance patient outcomes and optimize the healthcare system by elevating the current standard of care. The company is led by seasoned veterans in both research and development and commercialization within the respiratory sector.
How much funding has Telesair raised?
Telesair has raised a total of $25M across 2 funding rounds:
Series A
$22M
Private Equity
$3M
Series A (2023): $22M with participation from Berkeley Catalyst Fund and ShangBay Capital
Private Equity (2026): $3M, investors not publicly disclosed
Key Investors in Telesair
Berkeley Catalyst Fund
Berkeley Catalyst Fund is a venture capital firm based in Cupertino, California, known for supporting entrepreneurial startups.
ShangBay Capital
ShangBay Capital is a venture capital company specializing in medical devices, biotechnology, and healthcare, with a focus on seed and early-stage industries. It was founded in 2015 and is headquartered in Palo Alto, California.
What's next for Telesair?
With its recent major strategic investment, Telesair is poised for significant expansion and further development of its next-generation respiratory treatment system. This backing is expected to fuel advancements in product innovation, market penetration, and operational scaling. The company's focus on improving patient mobility and recovery times aligns with critical healthcare needs, suggesting a strong trajectory for future growth and adoption across various healthcare settings.
See full Telesair company page
